This is the first of a series I’m calling “Speaking Out.” The idea is to give even more prominence to people who are bravely using their voices to stand up for science, medicine, and the health of our nation.
Closed captions (㏄) for the above video and a transcript option (📄) can be found beneath the video playback control bar above.
Today, I was pleased to be joined by New York Times staff writer Jeneen Interlandi and pediatric infectious diseases specialist Dr. Jon Mannheim.
We discussed Jeneen’s major story, “The Trump Administration’s War on Science Has a Human Cost,” which ran this weekend and for which Jon was a quoted on-the-record source.
The big thing: we need people to understand the human cost of the Trump administration’s attack on US science. That’s what made Jeneen’s piece so important. It’s also why we want to cheer Jon on for his willingness to speak out in this way.
Below you’ll find some background followed by a summary of our conversation. Thank you for helping spread this important information!
Background: Since President Trump took office, we’ve covered his administration’s sustained attack on science and public health. For people in the Inside Medicine community, it’s easy to understand that deep cuts at the NIH, CDC, and elsewhere are dangerous. We understand what the numbers mean.
But what’s often missing from the coverage—here and in other outlets—is the perceptible human cost. That’s because some of the losses are not yet noticeable. In some instances, the destruction will never be obvious because we won’t see breakthroughs that failed to occur because funding was pulled. Moreover, the very people who might have delivered those breakthroughs have been intimidated into silence. Yes, we’ve been able to amplify important voices, but many remain afraid to speak out or don’t have the reach. For them, speaking out risks future funding because this administration has made no secret of its intentions.
That’s what makes this session so important.
Guests: New York Times staff writer Jeneen Interlandi has written a superb piece that, in my view, begins to address this gap. The piece, “The Trump Administration’s War on Science Has a Human Cost,” ran in Sunday’s print edition of the New York Times.1
Few mainstream media pieces have gone this deeply into explaining both the science and the scientists under attack. I’m looking forward to discussing it with the author and a prominent source in the piece, Dr. Jon Mannheim, a pediatrician specializing in HIV.
Summary & Highlights.
Aided by ChatGPT.
Welcome + why we launched “Speaking Out” (0:32)
We opened by explaining that Inside Medicine has tracked the Trump administration’s assault on science and public health, but that numbers alone don’t translate for many people—and that we need first-person stories from the scientists and clinicians living the consequences.
The core problem: the people who need to speak are scared to (1:32)
We laid out the “double-edged sword”: public accountability requires people to talk, but researchers and public servants worry that speaking out will cost them grants, jobs, or future opportunities—so the harm stays abstract.
Bringing in Jeneen Interlandi: why she wrote this, and why Chicago (3:17)
We asked Jeneen Interlandi how the piece came together, and she described an editorial push to capture the human cost of NIH cuts—then finding access through a Northwestern-based HIV prevention researcher, which naturally rooted the reporting in Chicago.
The “temporary blip” illusion—and why that’s wrong (7:32)
We dug into how grant reinstatements and court headlines can create false reassurance; even when money returns, the interrupted work, lost staff, and abandoned momentum create damage that doesn’t simply reverse.
Why Trump 1.0 could sound pro-HIV while Trump 2.0 is different (9:02)
We explored the idea that the earlier “end HIV by 2030” messaging reflected inattentiveness that allowed competent people to quietly build programs—whereas post-COVID politics made public health a target rather than an afterthought.
Framing, DEI, and the category error people keep making (12:01)
We argued that many skeptics will endorse “reduce HIV morbidity and mortality” in the abstract, but recoil when the work is described as studying marginalized communities—even though that work is often exactly what makes the first goal achievable.
“DEI” vs “health equity”: two different things (14:03)
We emphasized the distinction between diversifying scientific ranks and reducing health gaps—and noted how blunt “keyword” approaches (e.g., anything with “equity”) can gut legitimate public-health and implementation research.
Dr. Jon Mannheim joins: safety-net reality and Medicaid dread (17:43)
Dr. Jon Mannheim described the atmosphere inside a county hospital: leadership-to-frontline anxiety about Medicaid cuts, looming service loss, and the bottom-line question of who will become harder—or impossible—to treat.
The meds exist; the system to deliver them is what’s being cut (19:16)
We used PrEP and long-acting options as the example: breakthroughs don’t end epidemics by themselves—patients still need access, follow-up, transportation, phones, time off work, and clinics that can keep doors open.
Stigma and behavior change: “best drug in the world” still fails without trust (22:12)
We talked through how communities can resist PrEP for social and cultural reasons, and why behavioral and implementation science isn’t fluff—it’s the difference between a miracle drug on paper and prevention in the real world.
Respect is self-interest: why dignity and language matter to disease control (25:42)
We made the pragmatic case that humanizing people—down to basics like respectful interaction—can determine whether they engage with care, which ultimately affects everyone’s risk in a shared society.
ICE as a public-health accelerant (27:31)
Dr. Mannheim described fear-driven avoidance: patients skipping clinic because of ICE presence and targeting, with downstream consequences for TB and HIV—diseases that don’t stay contained within the communities being pressured.
How fast “untreated” becomes “AIDS again” (29:30)
We asked the practical timeline, and Dr. Mannheim explained it can range from months to years, with many patients getting into serious trouble around the one-year mark—highlighting why delayed harm is still real harm.
Prevention isn’t just “cost-effective”—it’s often cost-saving (31:22)
We walked through the plain-language economics: targeted prevention and delivery infrastructure can save money compared with ICU admissions for opportunistic infections—and research helps define who benefits most and how to reach them.
Targeting hotspots works: “go where the virus is” principle (32:49)
We discussed how concentrated HIV burden allows high-return investment—an approach aligned with classic infectious-disease strategy: focus resources where transmission is, not where it’s politically comfortable.
The unglamorous MVPs: social workers, case managers, and the scaffolding of care (39:12)
Dr. Mannheim made the point we kept returning to: clinicians aren’t the linchpin—support staff arranging rides, phones, outreach, food support, and continuity are what make prevention and treatment actually happen.
“Solved problems” can become unsolved again (40:08)
We highlighted perinatal HIV transmission and adolescent infections as fragile wins—dependent on systems that can be dismantled fast and rebuilt slowly, if at all.
Brain drain: losing talent to industry and to other countries (44:17)
We closed on the slow-motion catastrophe of expertise leaving government—and leaving the US—hollowing out the NIH/CDC ecosystem that made the country a global research magnet after World War II.
Call to action (48:14)
We told viewers the recording would be available on Inside Medicine with no paywall, thanked Jeneen Interlandi and Dr. Jon Mannheim, and framed the series mission plainly: we need more people to speak out now—or we’ll regret how quiet we were later.
